Oral Enzyme Ribaxamase for Preventing Clostridium Difficile Infection

July 27, 2017 | Technology Forecasts


![](http://www.ecri.org/_catalogs/masterpage/Images/Packages/HTAISImages/41433.gif)Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 4(Expected to be used by 60% to 80% of eligible patients)

ECRI Institute estimates ribaxamase (SYN-004; Synthetic Biologics, Inc., Rockville, MD, USA) might be coadministered routinely with intravenous (IV) beta lactams (more than 118 million doses in the United States annually) to about 60% to 80% of eligible patients, mostly those at high risk of Clostridium difficile infection (CDI). This might equate to more than 71 million daily doses of ribaxamase given annually. Utilization will be largely determined by ongoing and future studies demonstrating the safety and efficacy of ribaxamase, as well as the return on investment it yields for payers and providers.

Estimated Adoption Status: 1 (Early...

Access Full Content

Contact us today at 610.825.6000.